Psychedelic science in post-COVID-19 psychiatry
Open accessThe DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
The medium- to long-term consequences of COVID-19 are not yet known, though an increase in mental health problems are predicted. Multidisciplinary strategies across socio-economic and psychological levels may be needed to mitigate the mental health burden of COVID-19. Preliminary evidence from the rapidly progressing field of psychedelic science shows that psilocybin therapy offers a promising transdiagnostic treatment strategy for a range of disorders with restricted and maladaptive habitual patterns of cognition and behaviour, notably depression, addiction and obsessive compulsive disorder. The COMPASS Pathways (COMPASS) phase 2b double-blind trial of psilocybin therapy in antidepressant-free, treatment-resistant depression (TRD) is underway to determine the safety, efficacy and optimal dose of psilocybin. Results from the Imperial College London Psilodep-RCT comparing the efficacy and mechanisms of action of psilocybin therapy to the selective serotonin reuptake inhibitor (SSRI) escitalopram will soon be published. However, the efficacy and safety of psilocybin therapy in conjunction with SSRIs in TRD is not yet known. An additional COMPASS study, with a centre in Dublin, will begin to address this question, with potential implications for the future delivery of psilocybin therapy. While at a relatively early stage of clinical development, and notwithstanding the immense challenges of COVID-19, psilocybin therapy has the potential to play an important therapeutic role for various psychiatric disorders in post-COVID-19 clinical psychiatry.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
COVID-19 pandemic and mental health consequences: Systematic review of the current evidence
Vindegaard, N., & Benros, M. E. (2020) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2020.05.048 · Cited by 3,221
Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Cosimano, M. P., & Klinedinst, M. A. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116675513 · Cited by 2,201 · cited 1×
“…self-reflecting ‘ego’, induced by psilocybin, can lead to profound experiences of connectivity to others and the environment (Erritzoe et al. 2018, Griffiths et al. 2006, 2016, Grob et al. 2011, Kettner et al. 2019, Smigielski et al. 2019) and can be harnessed by psilocybin therapy to…”
BackgroundGriffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684
Carhart-Harris, R. L., Bolstridge, M., Rucker, J., Day, C. M. J., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J. A., Forbes, B., Feilding, A., et al. (2016) · The Lancet Psychiatry · doi:10.1016/s2215-0366(16)30065-7 · Cited by 1,540 · cited 1×
“Accumulating clinical data shows that psilocybin therapy may be an effective therapeutic strategy across a range of disorders, including depression (Carhart-Harris et al. 2016, Davis et al. 2019), obsessive compulsive disorder (Moreno et al. 2006) and addiction disorders (Garcia-Romeu et al. 2019,…”
BackgroundThe NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472 · cited 1×
“Moreover, given the transdiagnostic potential, a dimensional framework (Insel, 2014) that aligns with bio-psycho signatures could also be leveraged to enhance the targeted application of psilocybin therapy and further unravel themechanisms underpinning the acute and persistent therapeutic effects.”
BackgroundPsychedelics promote structural and functional neural plasticity
Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., Burbach, K. F., Soltanzadeh Zarandi, S., Sood, A., Paddy, M. R., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.05.022 · Cited by 1,207
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206 · cited 1×
“…by psilocybin, can lead to profound experiences of connectivity to others and the environment (Erritzoe et al. 2018, Griffiths et al. 2006, 2016, Grob et al. 2011, Kettner et al. 2019, Smigielski et al. 2019) and can be harnessed by psilocybin therapy to re-conceptualise restricted and…”
BackgroundREBUS and the anarchic brain: Toward a unified model of the brain action of psychedelics
Carhart-Harris, R. L., & Friston, K. J. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.017160 · Cited by 1,180
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up
Carhart-Harris, R. L., Bolstridge, M., Day, C. M. J., Rucker, J., Watts, R., Erritzoe, D. E., Kaelen, M., Giribaldi, B., Bloomfield, M., Pilling, S., et al. (2018) · Psychopharmacology · doi:10.1007/s00213-017-4771-x · Cited by 970
González-Maeso, J., Weisstaub, N. V., Zhou, M., Chan, P., Ivic, L., Ang, R., Lira, A., Bradley-Moore, M., Ge, Y., Zhou, Q., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.01.008 · Cited by 925 · cited 1×
“…shown that serotonergic psychedelics, including psilocybin, can induce hippocampal neurogenesis (Catlow et al. 2013, Morales-Garcia et al. 2017, Vaidya et al. 1997), promote dendritic spine growth and stimulate synapse formation in the prefrontal cortex (González-Maeso et al. 2007, Ly et al. 2018).”
BackgroundSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789 · cited 2×
“…data shows that psilocybin therapy may be an effective therapeutic strategy across a range of disorders, including depression (Carhart-Harris et al. 2016, Davis et al. 2019), obsessive compulsive disorder (Moreno et al. 2006) and addiction disorders (Garcia-Romeu et al. 2019, Johnson et al. 2017).”
BackgroundTraumatic stress in the age of COVID-19: A call to close critical gaps and adapt to new realities.
Horesh, D., & Brown, A. D. (2020) · Psychological Trauma: Theory, Research, Practice, and Policy · doi:10.1037/tra0000592 · Cited by 742
Serotonin and brain function: a tale of two receptors
Carhart-Harris, R., & Nutt, D. (2017) · Journal of Psychopharmacology · doi:10.1177/0269881117725915 · Cited by 739
Long-term follow-up of psilocybin-facilitated smoking cessation
Johnson, M. W., Garcia-Romeu, A., & Griffiths, R. R. (2017) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2016.1170135 · Cited by 696
Hasler, F., Grimberg, U., Benz, M. A., Huber, T., & Vollenweider, F. X. (2004) · Psychopharmacology · doi:10.1007/s00213-003-1640-6 · Cited by 451
Emotions and brain function are altered up to one month after a single high dose of psilocybin.
Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020) · Scientific Reports · doi:10.1038/s41598-020-59282-y · Cited by 375 · cited 4×
“…the white matter of the cerebral hemispheres and situated between the putamen and the insular cortex, with a rich supply of 5-HT2A receptors and glutamatergic connectivity to the cerebral cortex, and thought to be associated with cognitive task switching (Barrett et al. 2020b, Krimmel et al. 2019).”
BackgroundInfluentialPrediction of Psilocybin Response in Healthy Volunteers
Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030800 · Cited by 369
Kraehenmann, R., Preller, K. H., Scheidegger, M., Pokorny, T., Bosch, O. G., Seifritz, E., & Vollenweider, F. X. (2015) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.04.010 · Cited by 323
Effects of psilocybin therapy on personality structure
Erritzoe, D., Roseman, L., Nour, M. M., MacLean, K., Kaelen, M., Nutt, D. J., & Carhart‐Harris, R. L. (2018) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.12904 · Cited by 267
Effects of psilocybin on hippocampal neurogenesis and extinction of trace fear conditioning
Catlow, B. J., Song, S., Paredes, D. A., Kirstein, C. L., & Sanchez-Ramos, J. (2013) · Experimental Brain Research · doi:10.1007/s00221-013-3579-0 · Cited by 266 · cited 1×
“…2019, Meinhardt et al. 2020), preclinical data have shown that serotonergic psychedelics, including psilocybin, can induce hippocampal neurogenesis (Catlow et al. 2013, Morales-Garcia et al. 2017, Vaidya et al. 1997), promote dendritic spine growth and stimulate synapse formation in the prefrontal…”
BackgroundMason, N. L., Kuypers, K. P. C., Müller, F., Reckweg, J., Tse, D. H. Y., Toennes, S. W., Hutten, N. R. P. W., Jansen, J. F. A., Stiers, P., Feilding, A., et al. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0718-8 · Cited by 258 · cited 2×
“2018), and a recent magnetic resonance spectroscopy study in healthy humans found that psilocybin administrationwas associatedwith increased glutamate in the medial prefrontal cortex (Mason et al. 2020).”
BackgroundSmigielski, L., Scheidegger, M., Kometer, M., & Vollenweider, F. X. (2019) · NeuroImage · doi:10.1016/j.neuroimage.2019.04.009 · Cited by 248 · cited 1×
“…experiences of connectivity to others and the environment (Erritzoe et al. 2018, Griffiths et al. 2006, 2016, Grob et al. 2011, Kettner et al. 2019, Smigielski et al. 2019) and can be harnessed by psilocybin therapy to re-conceptualise restricted and maladaptive habitual patterns of cognition…”
BackgroundIncreased amygdala responses to emotional faces after psilocybin for treatment-resistant depression
Roseman, L., Demetriou, L., Wall, M. B., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.12.041 · Cited by 230 · cited 2×
“…an open-label study of 19 subjects with treatment-resistant depression (TRD) showed that psilocybin increased amygdala responses to emotional faces (Roseman et al. 2018) and decreased functional connectivity between the ventromedial prefrontal cortex and the right amygdala 1 day after psilocybin…”
Bouso, J. C., Palhano-Fontes, F., Rodríguez-Fornells, A., Ribeiro, S., Sanches, R., Crippa, J. A. S., Hallak, J. E. C., de Araujo, D. B., & Riba, J. (2015) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2015.01.008 · Cited by 218 · cited 1×
“Similarly, the impact of regular psychedelic use on the brain is limited (Bouso et al. 2015; Halpern et al. 2005).”
BackgroundMorales-García, J. A., de la Fuente Revenga, M., Alonso-Gil, S., Rodríguez-Franco, M. I., Feilding, A., Perez-Castillo, A., & Riba, J. (2017) · Scientific Reports · doi:10.1038/s41598-017-05407-9 · Cited by 175 · cited 1×
“…2020), preclinical data have shown that serotonergic psychedelics, including psilocybin, can induce hippocampal neurogenesis (Catlow et al. 2013, Morales-Garcia et al. 2017, Vaidya et al. 1997), promote dendritic spine growth and stimulate synapse formation in the prefrontal cortex…”
BackgroundMartinotti, G., Santacroce, R., Pettorruso, M., Montemitro, C., Spano, M., Lorusso, M., Di Giannantonio, M., & Lerner, A. (2018) · Brain Sciences · doi:10.3390/brainsci8030047 · Cited by 171
Effects of serotonin 2A/1A receptor stimulation on social exclusion processing
Preller, K. H., Pokorny, T., Hock, A., Kraehenmann, R., Stämpfli, P., Seifritz, E., Scheidegger, M., & Vollenweider, F. X. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1524187113 · Cited by 169
Psychedelics and Immunomodulation: Novel Approaches and Therapeutic Opportunities
Szabo, A. (2015) · Frontiers in Immunology · doi:10.3389/fimmu.2015.00358 · Cited by 150
Halpern, J. H., Lerner, A. G., & Passie, T. (2016) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2016_457 · Cited by 133 · cited 5×
“A review of hallucinogen persisting perception disorder (HPPD) and an exploratory study of subjects claiming symptoms of HPPD. Current Topics in Behavioral Neurosciences 36, 333–360.”
BackgroundInfluentialOrsolini, L., Papanti, G. D., De Berardis, D., Guirguis, A., Corkery, J. M., & Schifano, F. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00240 · Cited by 99 · cited 1×
“5-HT2AR antagonists, such as ketanserin, block the therapeutic effect of psilocybin (Preller et al. 2017), whereas the partial 5-HT1A agonist buspirone may exert inhibitory effects (Pokorny et al. 2016).”
BackgroundCoronavirus disease: challenges for psychiatry
Kelly, B. D. (2020) · The British Journal of Psychiatry · doi:10.1192/bjp.2020.86 · Cited by 80 · cited 2×
“2020, Türközer & Öngür, 2020), with an excess burden on vulnerable groups (Kelly, 2020).”
BackgroundBonson, K. R., & Murphy, D. L. (1995) · Behavioural Brain Research · doi:10.1016/0166-4328(96)00102-7 · Cited by 76
Psilocybin and LSD have no long-lasting effects in an animal model of alcohol relapse
Meinhardt, M. W., Güngör, C., Skorodumov, I., Mertens, L. J., & Spanagel, R. (2020) · Neuropsychopharmacology · doi:10.1038/s41386-020-0694-z · Cited by 65 · cited 1×
“…of 19 subjects with treatment-resistant depression (TRD) showed that psilocybin increased amygdala responses to emotional faces (Roseman et al. 2018) and decreased functional connectivity between the ventromedial prefrontal cortex and the right amygdala 1 day after psilocybin (Mertens et al. 2020).”
BackgroundKelly, J. R., Keane, V. O., Cryan, J. F., Clarke, G., & Dinan, T. G. (2019) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2019.04.006 · Cited by 65
Self-citationHistoric psychedelic drug trials and the treatment of anxiety disorders.
Weston, N. M., Gibbs, D., Bird, C. I. V., Daniel, A., Jelen, L. A., Knight, G., Goldsmith, D., Young, A. H., & Rucker, J. J. (2020) · Depression and Anxiety · doi:10.1002/da.23065 · Cited by 38 · cited 1×
“In addition, clinical trials are underway to investigate psilocybin therapy in anorexia nervosa (NCT04052568) and there may be a role for psilocybin therapy in the treatment of anxiety disorders (Weston et al. 2020).”
Background
Cited by
Kettner, H., Rosas, F. E., Timmermann, C., Kärtner, L., Carhart-Harris, R. L., & Roseman, L. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.623985 · Cited by 221
Psychedelic perceptions: mental health service user attitudes to psilocybin therapy
Corrigan, K., Haran, M., McCandliss, C., McManus, R., Cleary, S., Trant, R., Kelly, Y., Ledden, K., Rush, G., O’Keane, V., et al. (2022) · Irish Journal of Medical Science (1971 -) · doi:10.1007/s11845-021-02668-2 · Cited by 84
Self-citationPsychedelic therapy's transdiagnostic effects: A research domain criteria (RDoC) perspective
Kelly, J. R., Gillan, C. M., Prenderville, J., Kelly, C., Harkin, A., Clarke, G., & O'Keane, V. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.800072 · Cited by 69
“Whereas exploratory studies are underway to determine the safety and efficacy of psilocybin therapy in conjunction with SSRI’s (102).”
BackgroundSelf-citationCarhart-Harris, R. L., Wagner, A. C., Agrawal, M., Kettner, H., Rosenbaum, J. F., Gazzaley, A., Nutt, D. J., & Erritzoe, D. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211008567 · Cited by 51
Metadata
- Authors
- Kelly, J. R., Crockett, M. T., Alexander, L., Haran, M., Baker, A., Burke, L., Brennan, C., & O’Keane, V.
- Venue
- Irish Journal of Psychological Medicine
- Publisher
- Cambridge University Press (CUP)
- Published
- 2020-08-19
- Volume
- 38
- Issue
- 2
- Pages
- 93-98
- ISSN
- 0790-9667 (ISSN-L)
- 2051-6967
- OpenAlex
- W3054886531
- Cited by
- 16
- References
- 35
- FWCI
- 1.12
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.